Home  |  Contact

Cellosaurus OVCA429 (CVCL_3936)

[Text version]

Cell line name OVCA429
Synonyms OVCA 429; OvCA 429; OVCA-429; OVCAR-429; OVCAR 429; OVCAR429; OV429
Accession CVCL_3936
Resource Identification Initiative To cite this cell line use: OVCA429 (RRID:CVCL_3936)
Comments Part of: MD Anderson Cell Lines Project.
Doubling time: 34.58 hours (https://www.synapse.org/#!Synapse:syn2347014).
Omics: Deep RNAseq analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Ovary.
Disease Ovarian cystadenocarcinoma (NCIt: C5228)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_JY92 (OVCA429/GFP)CVCL_CZ99 (OVCA429/T40)CVCL_CZ98 (OVCA429/TxT50)
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): PubMed=22710073; PubMed=25877200; PubMed=30485824

Markers:
AmelogeninX
CSF1PO12,13 (PubMed=22710073; PubMed=25877200)
12,13,14 (PubMed=30485824)
D2S133819,20
D3S135815,16
D5S81811,12
D7S82011,12
D8S117914,15
D13S3177,12
D16S53912
D18S5114
D19S43313
D21S1130
FGA24
Penta D13,14
Penta E12
TH019
TPOX9,11
vWA16,18

Run an STR similarity search on this cell line
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=7028788; DOI=10.1172/JCI110380
Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C.
Reactivity of a monoclonal antibody with human ovarian carcinoma.
J. Clin. Invest. 68:1331-1337(1981)

PubMed=6346879; DOI=10.1016/0002-9378(83)90999-7
Berkowitz R., Kabawat S., Lazarus H., Colvin R.B., Knapp R.C., Bast R.C. Jr.
Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line.
Am. J. Obstet. Gynecol. 146:607-612(1983)

PubMed=1536252; DOI=10.1016/0002-9378(92)91697-9
Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P., Arrick B.A., Clarke-Pearson D.L., Bast R.C. Jr.
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.
Am. J. Obstet. Gynecol. 166:676-684(1992)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000)

PubMed=12080474; DOI=10.1038/sj.onc.1205542
Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I., Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J., Auersperg N., Birrer M.J.
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.
Oncogene 21:4435-4447(2002)

PubMed=12960427; DOI=10.1091/mbc.E03-05-0279
Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.
Gene expression patterns in ovarian carcinomas.
Mol. Biol. Cell 14:4376-4386(2003)

PubMed=16380993; DOI=10.1002/ijc.21671
Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X., Ng W.-C., Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.
Selenium binding protein 1 in ovarian cancer.
Int. J. Cancer 118:2433-2440(2006)

PubMed=16382445; DOI=10.1002/gcc.20300
Wang Y.C., Juric D., Francisco B., Yu R.X., Duran G.E., Chen G.K., Chen X., Sikic B.I.
Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.
Genes Chromosomes Cancer 45:365-374(2006)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R., Easwaran H., Baylin S.B., Slamon D., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

Cross-references
Ontologies BTO; BTO:0002564
EFO; EFO_0006721
Biological sample resources BioSample; SAMN03470937
Chemistry resources PharmacoDB; OvCA429_1214_2019
Gene expression databases ArrayExpress; E-MTAB-2706
GEO; GSM95439
GEO; GSM659391
GEO; GSM711704
GEO; GSM851929
Other Wikidata; Q54936983
Polymorphism and mutation databases Cosmic; 924146
Cosmic; 927567
Cosmic; 1223315
Cosmic; 1328064
Cosmic; 1434898
Cosmic; 2074245
Entry history
Entry creation04-Apr-2012
Last entry update02-Jul-2020
Version number19